Biosimilar Billing Proposal For Medicare Contrary To Statute, Sen. Hatch Says
This article was originally published in The Pink Sheet Daily
Strong words from the Senate Finance Committee chairman suggest the confirmation process for Andrew Slavitt to be CMS administrator could become a showdown over biosimilar billing codes should the agency stick with its plan to put all biosimilars referencing the same innovator product into the same code.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.